241 related articles for article (PubMed ID: 9379350)
1. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
Yukawa E; Honda T; Ohdo S; Higuchi S; Aoyama T
J Pharm Pharmacol; 1997 Aug; 49(8):751-6. PubMed ID: 9379350
[TBL] [Abstract][Full Text] [Related]
2. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data.
Yukawa E; Aoyama T
J Clin Pharmacol; 1996 Aug; 36(8):752-9. PubMed ID: 8877681
[TBL] [Abstract][Full Text] [Related]
3. A feasibility study of the multiple-peak approach for pharmacokinetic screening: population-based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data.
Yukawa E
J Pharm Pharmacol; 1995 Dec; 47(12A):1048-52. PubMed ID: 8932693
[TBL] [Abstract][Full Text] [Related]
4. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics.
Yukawa E; To H; Ohdo S; Higuchi S; Aoyama T
J Clin Pharmacol; 1997 Dec; 37(12):1160-7. PubMed ID: 9506012
[TBL] [Abstract][Full Text] [Related]
5. Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling.
Yukawa E; To H; Ohdo S; Higuchi S; Aoyama T
Eur J Clin Pharmacol; 1998 Mar; 54(1):69-74. PubMed ID: 9591934
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients.
Jankovic SM; Jovanovic D; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2008 Nov; 30(9):707-13. PubMed ID: 19229380
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients.
Yukawa E; Nonaka T; Yukawa M; Higuchi S; Kuroda T; Goto Y
J Clin Pharm Ther; 2003 Dec; 28(6):497-504. PubMed ID: 14651674
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.
EL Desoky ES; Fuseau E; EL Din Amry S; Cosson V
Eur J Clin Pharmacol; 2004 Jan; 59(11):783-90. PubMed ID: 14673555
[TBL] [Abstract][Full Text] [Related]
9. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
[TBL] [Abstract][Full Text] [Related]
10. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data.
Blanco-Serrano B; Otero MJ; Santos-Buelga D; García-Sánchez MJ; Serrano J; Domínguez-Gil A
Biopharm Drug Dispos; 1999 Jul; 20(5):233-40. PubMed ID: 10594867
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
Jankovic SM; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
[TBL] [Abstract][Full Text] [Related]
12. A model for estimating individualized valproate clearance values in children.
Botha JH; Gray AL; Miller R
J Clin Pharmacol; 1995 Oct; 35(10):1020-4. PubMed ID: 8568010
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of valproate in Mexican children with epilepsy.
Correa T; Rodríguez I; Romano S
Biopharm Drug Dispos; 2008 Dec; 29(9):511-20. PubMed ID: 19067436
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.
Jiao Z; Shi XJ; Zhao ZG; Zhong MK
J Clin Pharm Ther; 2004 Jun; 29(3):247-56. PubMed ID: 15153086
[TBL] [Abstract][Full Text] [Related]
15. Estimation of apparent clearance of valproic acid in adult Saudi patients.
Alqahtani S; Alandas N; Alsultan A
Int J Clin Pharm; 2019 Aug; 41(4):1056-1061. PubMed ID: 31222537
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interactions among phenobarbital, carbamazepine, and valproic acid in pediatric Japanese patients: clinical considerations on steady-state serum concentration-dose ratios.
Yukawa E; Hokazono T; Satou M; Ohdo S; Higuchi S; Aoyama T
Am J Ther; 2000 Sep; 7(5):303-8. PubMed ID: 11317175
[TBL] [Abstract][Full Text] [Related]
17. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
Otoul C; De Smedt H; Stockis A
Epilepsia; 2007 Nov; 48(11):2111-5. PubMed ID: 17651416
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoepidemiologic investigation of clonazepam relative clearance by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients.
Yukawa E; Satou M; Nonaka T; Yukawa M; Ohdo S; Higuchi S; Kuroda T; Goto Y
J Clin Pharmacol; 2002 Jan; 42(1):81-8. PubMed ID: 11808828
[TBL] [Abstract][Full Text] [Related]
19. Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics.
Brzaković BB; Vezmar Kovačević SD; Vučićević KM; Miljković BR; Martinović ZJ; Pokrajac MV; Prostran MŠ
J Clin Pharm Ther; 2012 Dec; 37(6):693-7. PubMed ID: 22583007
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing valproate pharmacokinetics in children and adults.
Jankovic SM; Milovanovic JR; Jankovic S
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):767-75. PubMed ID: 20979937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
